Source: *Global Kinetics Corporation*

May 07, 2019 09:00 ET

Global Kinetics Corporation's PKG® Provides Clinically Meaningful Improvement in Symptom Assessment, Management, Medication Optimization, and Patient-Clinician Conversations in Parkinson's Disease

Data Recently Presented at the 2019 American Academy of Neurology's Annual Meeting
APPRISE Clinical Study Continues Enrollment at 10 Movement Disorder Clinics in the U.S.

PORTSMOUTH, N.H. and LONDON and MELBOURNE, Australia, May 07, 2019 (GLOBE NEWSWIRE) -- Global Kinetics today reported data that was recently presented at poster presentation sessions during the 2019 American Academy of Neurology's (AAN) Annual Meeting in Philadelphia, PA, May 4 – 10, 2019 and the 2019 Parkinson Study Group (PSG) in Phoenix, AZ, April 5 – 8, 2019. The two posters highlighted how the Company's Personal KinetiGraph® (PKG®) technology provided clinically meaningful improvements in Parkinson's disease (PD) symptom assessment, management and medication optimization, and also enhanced patient-clinician conversations.

PKG is a first-of-its-kind, wearable, FDA-cleared and CE-marked technology that provides clinicians with a passive, continuous, objective, ambulatory assessment of the treatable and disabling symptoms of PD, including bradykinesia, dyskinesia, and tremor. To date, more than 40,000 patient PKG reports have been recorded, enabling more than 200 Parkinson's specialist clinics around the world to further tailor therapy and improve management for their PD patients.

The poster presented at AAN, "Objective Data in Parkinson's Disease: A Description of Over 27,000 Parkinson's Symptom Scores Across the World Using the Personal KinetiGraph® (PKG®)," reported data from study in 27,834 de-identified PKG reports worldwide from 2012 – 2018. Researchers found that a meaningful proportion of patients had suboptimal PD motor symptoms management at baseline, with 54% having uncontrolled but likely treatable bradykinesia and 10% showing uncontrolled, likely treatable dyskinesia. For a sub-set of those with multiple PKG use, the subsequent PKG use showed a significant improvement in PKG scores indicating more controlled motor symptoms, demonstrating that the objective measurement data provided by the technology can be used to enhance clinical decision making to improve motor symptom management.

A second poster, presented in April at the 2019 Parkinson Study Group (PSG), and titled, "An Observational Study of PKG Movement Recording System Use in Routine Clinical Care of Patients with Parkinson's Disease," highlighted the results of a study conducted at the University of California-Los Angeles (UCLA) and University of California-Irvine. A combined 63 patients with PD were assessed every three months and wore a PKG for six continuous days prior to a visit. Physicians found that the PKG enabled improved dialogue with patients in 59% of visits, and improved the ability to assess treatment impact and patient symptoms in 38% and 33% of visits, respectively. In addition, 53% of patients

stated they agreed or strongly agreed in PKG training, usability, performance and satisfaction, while 40% of patients felt that PKG had a very valuable impact on their care. The PKG reports were used to make 74 treatment plan changes in 79% of patients across 84% of visits. Most common treatment changes included the addition of at least one medication or changed dosage and timing of medications.

John Schellhorn, CEO of Global Kinetics Corporation, said, “At Global Kinetics, we are committed to serving the Parkinson’s disease community and providing access to our PKG, which can provide objective measurement in the clinical care setting and help optimize care in this neurodegenerative disease. These presentations underscore the value of PKG in providing valuable information about Parkinson’s movement symptoms and allowing neurologists and movement disorder specialists to have more meaningful conversations with their patients, which translates to optimized care.”

Global Kinetics is also currently enrolling patients in APPRISE, a prospective, multi-center, randomized controlled trial designed to evaluate the use of PKG plus medical history versus standard of care in the assessment of people diagnosed with PD. The aim of the study is to demonstrate that the use of objective measurement and monitoring with PKG positively influences treatment decisions by clinicians and ultimately impacts changes in patient outcomes measured by common PD assessments, including the Movement Disorder Specialist – Unified PD Rating Scale (MDS-UPDRS), which is conducted during patient-clinician visits, and the PD Questionnaire-39 (PDQ-39), which is self-reported by patients. APPRISE is ongoing at 10 U.S. Movement Disorder clinics and is designed to enroll up to 430 patients. For additional information about the trial, please visit: https://clinicaltrials.gov/ct2/show/NCT03741920.

Stuart H. Isaacson, M.D., Director of the Parkinson’s Disease and Movement Disorders Center of Boca Raton in Florida, and an investigator in the APPRISE study, commented, “Our team is excited to be a part of this post-marketing study, which will contribute to the growing body of data supporting the value of continuous objective monitoring in the management of patients with Parkinson’s disease. Use of the PKG in our clinic has enhanced conversations with our patients and our ability to determine when treatment plans should be adjusted to provide more optimal care.”

About Global Kinetics Pty Ltd.
Global Kinetics Pty Ltd. is committed to improving the lives of those with Parkinson’s disease with advanced medical technologies. The company was formed in 2007 to commercialize its lead product, the Personal KinetiGraph (PKG). The PKG enables the precise monitoring, quantification, and reporting of movement symptoms in Parkinson’s. To date, Global Kinetics has supported clinical decisions for doctors who have obtained more than 40,000 PKG reports for Parkinson’s disease, generating more than 6,000,000 hours of clinical data from our FDA-cleared, CE-marked PKG wearable device. Global Kinetics, a privately held company, is headquartered in Melbourne, Australia with offices in London, UK, Minneapolis, MN, and Portsmouth, NH, USA.

For more information, visit: www.globalkineticscorporation.com
Follow our LinkedIn updates: https://www.linkedin.com/company/globalkineticscorp

Media Contact
Lazar Partners
Chantal Beaudry / Amy Feldman
+1 (646) 871-8480 / +1 (212) 867-1779
GKC@lazarpartners.com